ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Sanofi, Regeneron’s Dupixent wins positive results in chronic spontaneous urticaria
July 30, 2021Sanofi and Regeneron’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent has demonstrated positive pivotal results in chronic spontaneous urticaria (CSU) – a chronic inflammatory skin disease. -
US breakthrough designation for ligelizumab in chronic spontaneous urticaria
January 18, 2021The US Food and Drug Administration (FDA) has granted Novartis’ ligelizumab a breakthrough therapy designation for the treatment of patients with chronic spontaneous urticaria (CSU) who have an inadequate response to H1-antihistamine treatment. -
Novartis takes Xolair follow-up into phase III hives trial
December 06, 2018Novartis says it intends to move a drug for chronic spontaneous urticaria (CSU), a severe form of hives, into a phase III programme on the strength of a mid-stage study......
Pharma Sources Insight January 2025
